MKGAF

Merck KGaA | Cotação de Ações

Última atualização17/04/2025, 16:58:59

PreçoUS$ 130,21

Variação (dia)-US$ 6,64 (-4.85%)▼

Min. 52 SemanasUS$ 118,05

Máx. 52 SemanasUS$ 200,56

Capitalização de mercado--

Endereço: Frankfurter Strasse 250, Darmstadt, 64293

Telefone: 49 6151 72 0

Funcionários: 59.020

Merck KGaAMKGAF

US$ 130,21

- 6,644,9%

17/04/2025 16:58:59

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 130,21

Valor de mercado--

AberturaUS$ 134,15

Preço máximoUS$ 130,21

Preço mínimoUS$ 130,21

VolumeUS$ 46

Fechamento anteriorUS$ 136,85

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Ações relacionadas

Merck KGaA

MKKGY ▼0.03% | US$ 29,08

CSL Limited

CMXHF ▲167.20% | US$ 167,20

Daiichi Sankyo Company, Limited

DSKYF ▲26.75% | US$ 26,75

Lonza Group AG

LZAGF ▲581.20% | US$ 581,20

Chugai Pharmaceutical Co., Ltd.

CHGCY ▼0.01% | US$ 22,50

Conheça os Planos e Preços personalizados para acessar recursos exclusivos

Explore nossos Planos e Preços para obter acesso a recursos exclusivos, atendendo às suas necessidades específicas. Oferecemos opções flexíveis para investidores de todos os níveis, garantindo que você tenha as ferramentas certas para otimizar sua estratégia de investimento.

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.